POLQ & eIF4E Assay
Oncology
CommercialAvailable
Key Facts
About Aurora Biolabs
Aurora Biolabs operates as a premier manufacturer and service provider in the life sciences research tools sector, focusing on enabling drug discovery through reliable, ISO 17025-certified reagents and assays. As a subsidiary of Structure Based Design, Inc. (SBD), it leverages decades of scientific expertise to offer assay development, protein expression, and a 145K-compound library screening service. The company is strategically positioned as a direct US manufacturer, ensuring quality control and cost-effective solutions for academic, biotech, and pharmaceutical research clients.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Mvasi (bevacizumab biosimilar) | Viatris | Approved |
| DRL-17822 | Dr. Reddy's Laboratories | Phase 2 |
| Biosimilar Portfolio | Zydus Lifesciences | Various |
| therascreen Solid Tumor | Qiagen | Commercial |
| GBR 830 | Glenmark Pharmaceuticals | Phase 1 |
| Bevacizumab Biosimilar | Glenmark Pharmaceuticals | Approved |
| Biosimilar (Bevacizumab) | Ipca Laboratories | Development |
| LockBody Platform Assets | Centessa Pharmaceuticals | Pre-clinical |
| Everolimus | Amneal Pharmaceuticals | Approved |
| Lenalidomide (Revlimid generic) | Amneal Pharmaceuticals | Approved |
| Alymsys (bevacizumab-maly) | Amneal Pharmaceuticals | Approved |
| Pemrydi RTU | Amneal Pharmaceuticals | Approved |